2023 World Conference on Lung Cancer (Posters)-P2.09. Efficacy and Safety of Aumolertinib as Second- Or Third-Line Therapy in EGFR T790M Negative/Unknown Non-small Cell Lung Cancer

P2.09. Efficacy and Safety of Aumolertinib as Second- Or Third-Line Therapy in EGFR T790M Negative/Unknown Non-small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

A retrospective study was conducted to assess the efficacy and safety of aumolertinib as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who were negative or unknown for the EGFR T790M mutation. The study included 31 patients who had progressed after previous treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Aumolertinib was administered at a dose of 110mg orally once daily. The primary endpoint was progression-free survival (PFS), and secondary endpoints included objective response rate (ORR), disease control rate (DCR), and safety.<br /><br />The results showed that among the 17 patients who received second-line aumolertinib treatment, the median PFS was 11.3 months, the ORR was 12%, and the DCR was 82%. In the subgroup of patients with brain metastases (n=8), the median PFS was 10.6 months, the ORR was 25%, and the DCR was 88%. Among the 14 patients who received third-line aumolertinib treatment, the median PFS was 6.3 months, the ORR was 0%, and the DCR was 79%. Overall survival (OS) data was not available at the time of the analysis.<br /><br />The most common adverse events observed were rash (12.9%) and diarrhea (16.1%), both of which were manageable. No grade 3 or higher adverse events were reported, and no new safety signals were identified.<br /><br />In conclusion, aumolertinib showed promising antitumor activity with manageable toxicity as second- or third-line therapy in patients with EGFR T790M-negative/unknown NSCLC, both with and without brain metastases. These findings suggest that aumolertinib may be a potential treatment option for this patient population.

Asset Subtitle

Jieran Long

Meta Tag

Speaker Jieran Long

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

retrospective study

efficacy

safety

aumolertinib

second-line therapy

third-line therapy

non-small cell lung cancer

EGFR T790M mutation

progression-free survival

objective response rate